Background: The aim of this study was to explore the inhibitory effect of baicalin on myocardial apoptosis induced by Ischemia-Reperfusion (I/R).Methods: Sprague Dawley rats' heart and myocardial cells I/R model were established in vivo and vitro, then 100 mg/kg and 10 μmol/l baicalin were administrated, respectively. The experiment was randomly divided into 4 groups (n=10): Control; I/R; IR+DMEM; and I/R+baicalin groups. Postoperation, the Left Ventricular (LV) End-Diastolic Pressure (LVEDP), the maximum velocity of LV contraction (dP/dtmax) and the maximum velocity of LV diastole (dP/dtmin) were recorded by the transthoracic echocardiography; the myocardial apoptosis percentage was analyzed by Annexin VFITC/ PI and TUNEL staining, and the apoptosis gene and protein were detected by RT-PCR and western blot. Furthermore, the protein expression of the calcium-sensing receptor (CaSR) and ERK1/2 phosphorylation were observed by western blot and Fura-2-acetoxymethyl ester. Moreover, primary rats’ cardiomyocytes were cultured and ERK1/2 specific inhibitor PD98059 was added to the culture medium. The cell survival rate, vitality and apoptosis were detected by MTT, lactate dehydrogenase (LDH) and TUNEL staining assay Kit, respectively.Results: Our present study showed that baicalin significantly improved LV hemodynamic parameters and myocardial apoptosis in myocardial I/R injury rats. Furthermore, we found that baicalin could down-regulate the protein expression of CaSR, but up-regulate the protein expression of ERK1/2. Furthermore, when the cells were pretreated with ERK1/2 inhibitor PD98059, the cells survival rate significantly decreased, but LDH activity and apoptosis significantly increased. The results indicated that the effect of baicalin on myocardial I/R injury could be inhibited by ERK1/2 inhibitor.Conclusion: In conclusion, our data suggests that baicalin attenuates I/R-induced myocardial injury maybe through the suppression of the CaSR/ERK1/2 signaling pathway.
11 April 2025 in European Journal of Cardiovascular Nursing
Aims: Although anxiety and depression are frequently linked to coronary heart disease, a network analysis of comorbid anxiety and depression and their association with quality of life (QoL) in patients undergoing percutaneous coronary intervention (PCI) remains unclear from the perspective of symptom interactions. We aimed to investigate the network structure and symptom patterns of anxiety and depression, and their relationship with QoL in patients undergoing PCI. Methods and results: This study included 528 patients undergoing PCI. The seven-item Generalized Anxiety Disorder Scale, nine-item Patient Health Questionnaire, and World Health Organization Quality of Life Questionnaire-Brief Version were used as measurement tools. The R software was used to construct and interpret the network structure. The symptoms ‘sleep disturbance,’ ‘irritability,’ and ‘uncontrollable worry’ showed the highest expected influence centrality. Three bridge symptoms were identified: ‘sleep disturbance,’ ‘excessive worry,’ and ‘trouble relaxing.’ Among the three strongest edges, two were associated with anxiety and depressive symptoms. Ten symptoms were directly associated with QoL, with ‘fatigue’ showing the strongest relationship. In the network comparison test, significant differences in global strength were observed between the male and female groups. Conclusion: ‘Sleep disturbance,’ plays a critical role in the current network, while ‘excessive worry,’ ‘trouble relaxing,’ and ‘fatigue’ were identified as key priorities owing to their high correlation with ‘sleep disturbance’ and QoL. Focusing on these symptoms may help mitigate the risk of multiple-symptom interactions and provide tailored intervention measures for patients undergoing PCI. Registration: Chinese Clinical Trial Registry: ChiCTR230007581